The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
The Biology Behind mTOR Inhibition in Sarcoma
Open accessAbstract
Learning Objectives: After completing this course, the reader will be able to: Discuss the function of the mTOR pathway in cancer cell growth and survival.Describe the potential mechanism of targeting this pathway by rapamycin and its derivatives for cancer therapy.Summarize the clinical trials performed with mTOR inhibitors in the treatment of sarcomas and suggest the future clinical development of these inhibitors in the treatment of sarcomas. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887
mTOR, translation initiation and cancer
Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209888 · Cited by 607
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481
Gene expression profiling of human sarcomas: insights into sarcoma biology.
Baird, K., Davis, S., Antonescu, C. R., Harper, U. L., Walker, R. L., Chen, Y., Glatfelter, A. A., Duray, P. H., & Meltzer, P. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1699 · Cited by 353
Cited by
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas
Serrano, C., Romagosa, C., Hernández‐Losa, J., Simonetti, S., Valverde, C., Moliné, T., Somoza, R., Pérez, M., Vélez, R., Vergés, R., et al. (2016) · Cancer · doi:10.1002/cncr.29733 · Cited by 59
Zhang, W., Xia, D., Li, Z., Zhou, T., Chen, T., Wu, Z., Zhou, W., Li, Z., Li, L., & Xu, J. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1855-z · Cited by 38
A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma
Olanich, M. E., & Barr, F. G. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.772136 · Cited by 39
Characterization of mTOR Activity and Metabolic Profile in Pediatric Rhabdomyosarcoma
Felkai, L., Krencz, I., Kiss, D. J., Nagy, N., Petővári, G., Dankó, T., Micsík, T., Khoor, A., Tornóczky, T., Sápi, Z., et al. (2020) · Cancers · doi:10.3390/cancers12071947 · Cited by 13
Metadata
- Authors
- Wan, X., & Helman, L. J.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-08-01
- Volume
- 12
- Issue
- 8
- Pages
- 1007-1018
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2143393758
- Cited by
- 180
- References
- 10
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Biology Behind mTOR Inhibition in Sarcoma. https://app.cochat.ai/papers/10.1634/theoncologist.12-8-1007
- The paper
- Wan, X., & Helman, L. J. (2007). The Biology Behind mTOR Inhibition in Sarcoma. The Oncologist. https://doi.org/10.1634/theoncologist.12-8-1007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.